DC-SCRIPT: Nuclear receptor modulation and prognostic significance in primary breast cancer

Journal of the National Cancer Institute

Volumn 102, Issue 1, 2010, Pages 54-68

  Ansems, M ^a   Hontelez, S ^a   Looman, M W G ^a   Karthaus, N ^a   Bult, P ^a   Bonenkamp, J J ^a   Jansen, J H ^a   Sweep, F C G J ^a   Span, P N ^a   Adema, Gosse J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; LUCIFERASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PORPHOBILINOGEN DEAMINASE; RETINOIC ACID RECEPTOR ALPHA; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; VALIDATION STUDY;

ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DNA, COMPLEMENTARY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; POLYMERASE CHAIN REACTION; PPAR GAMMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTOR ALPHA; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 74049113704     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp441     Document Type: Article

References (55)

1. Laudet V, Hanni C, Coll J, Catzefl is F, Stehelin D. Evolution of the nuclear receptor gene superfamily. EMBO J. 1992; 11 ( 3 ): 1003-1013.
2. Nagy L, Schule R, Gronemeyer H. Twenty years of nuclear receptors: Conference on Nuclear Receptors: from Chromatin to Disease. EMBO Rep. 2006; 7 ( 6 ): 579-584.
3. Sonoda J, Pei L, Evans RM. Nuclear receptors: decoding metabolic disease. FEBS Lett. 2008; 582 ( 1 ): 2-9.
4. Wang K, Wan YJ. Nuclear receptors and infl ammatory diseases. Exp Biol Med (Maywood). 2008; 233 ( 5 ): 496-506.
5. Turner NC, Jones AL. Management of breast cancer-part II. BMJ. 2008; 337 ( 7662 ): a540.
6. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006; 354 ( 3 ): 270-282.
7. Conzen SD. Minireview: nuclear receptors and breast cancer. Mol Endocrinol. 2008; 22 ( 10 ): 2215-2228.
8. Bourdeau V, Deschenes J, Laperriere D, Aid M, White JH, Mader S. Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells. Nucleic Acids Res. 2008; 36 ( 1 ): 76-93.
9. Turner NC, Jones AL. Management of breast cancer-part I. BMJ. 2008; 337 ( 7661 ): a421.
10. Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R. PRAME expression and clinical outcome of breast cancer. Br J Cancer. 2008; 99 ( 3 ): 398-403.
11. Girault I, Lerebours F, Amarir S, et al. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res. 2003; 9 ( 4 ): 1259-1266.
12. Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coacti-vator amplifi ed in breast and ovarian cancer. Science. 1997; 277 ( 5328 ): 965-968.
13. Lonard DM, Lanz RB, O'Malley BW. Nuclear receptor coregulators and human disease. Endocr Rev. 2007; 28 ( 5 ): 575-587.
14. Lonard DM, O'Malley BW. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell. 2007; 27 ( 5 ): 691-700.
15. O'Malley BW. Coregulators: from whence came these "master genes". Mol Endocrinol. 2007; 21 ( 5 ): 1009-1013.
16. Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003; 95 ( 5 ): 353-361.
17. Green AR, Burney C, Granger CJ, et al. The prognostic signifi cance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/ SMRT is an independent indicator of poor outcome. Breast Cancer Res Treat. 2008; 110 ( 3 ): 427-437.
18. Schug TT, Berry DC, Toshkov IA, Cheng L, Nikitin AY, Noy N. Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR. Proc Natl Acad Sci U S A. 2008; 105 ( 21 ): 7546-7551.
19. Triantis V, Trancikova DE, Looman MW, Hartgers FC, Janssen RA, Adema GJ. Identifi cation and characterization of DC-SCRIPT, a novel dendritic cell-expressed member of the zinc fi nger family of transcrip-tional regulators. J Immunol. 2006; 176 ( 2 ): 1081-1089.
20. Triantis V, Moulin V, Looman MW, Hartgers FC, Janssen RA, Adema GJ. Molecular characterization of the murine homologue of the DC-derived protein DC-SCRIPT. J Leukoc Biol. 2006; 79 ( 5 ): 1083-1091.
21. Chinnadurai G. CtBP family proteins: more than transcriptional corepres-sors. Bioessays. 2003; 25 ( 1 ): 9-12.
22. Lopez-Garcia J, Periyasamy M, Thomas RS, et al. ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases. Nucleic Acids Res. 2006; 34 ( 21 ): 6126-6136.
23. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 1990; 347 ( 6293 ): 558-561.
24. Chung YT, Keller EB. Regulatory elements mediating transcription from the Drosophila melanogaster actin 5C proximal promoter. Mol Cell Biol. 1990; 10 ( 1 ): 206-216.
25. Cato AC, Miksicek R, Schutz G, Arnemann J, Beato M. The hormone regulatory element of mouse mammary tumour virus mediates progesterone induction. EMBO J. 1986; 5 ( 9 ): 2237-2240.
26. Cato AC, Henderson D, Ponta H. The hormone response element of the mouse mammary tumour virus DNA mediates the progestin and androgen induction of transcription in the proviral long terminal repeat region. EMBO J. 1987; 6 ( 2 ): 363-368.
27. Kim JB, Wright HM, Wright M, Spiegelman BM. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci U S A. 1998; 95 ( 8 ): 4333-4337.
28. Tung L, Abdel-Hafi z H, Shen T, et al. Progesterone receptors (PR)-B and-A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. Mol Endocrinol. 2006; 20 ( 11 ): 2656-2670.
29. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestro-gens. Endocrinology. 1999; 140 ( 12 ): 5566-5578.
30. Sombroek CC, Stam AG, Masterson AJ, et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol. 2002; 168 ( 9 ): 4333-4343.
31. de Kok JB, Roelofs RW, Giesendorf BA, et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest. 2005; 85 ( 1 ): 154-159.
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25 ( 4 ): 402-408.
33. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classifi cation or prediction: standards for study design. J Natl Cancer Inst. 2008; 100 ( 20 ): 1432-1438.
34. Foekens JA, Atkins D, Zhang Y, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol. 2006; 24 ( 11 ): 1665-1671.
35. Greene F, Page D, Fleming I, et al. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
36. Span PN, Sweep FC, Wiegerinck ET, et al. Survivin is an independent prognostic marker for risk stratifi cation of breast cancer patients. Clin Chem. 2004; 50 ( 11 ): 1986-1993.
37. Massey FJ Jr. The Kolmogorov-Smirnov test for goodness of fi t. J Am Stat Assoc. 1951; 46 ( 253 ): 68-78.
38. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM. Nuclear receptor that identifi es a novel retinoic acid response pathway. Nature. 1990; 345 ( 6272 ): 224-229.
39. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957; 11 ( 3 ): 359-377.
40. Zhou Q, Stetler-Stevenson M, Steeg PS. Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro. Oncogene. 1997; 15 ( 1 ): 107-115.
41. Liu R, Takayama S, Zheng Y, et al. Interaction of BAG-1 with retinoic acid receptor and its inhibition of retinoic acid-induced apoptosis in cancer cells. J Biol Chem. 1998; 273 ( 27 ): 16985-16992.
42. Bonofi glio D, Cione E, Qi H, et al. Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. Am J Pathol. 2009; 175 ( 3 ): 1270-1280.
43. Hua S, Kittler R, White KP. Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell. 2009; 137 ( 7 ): 1259-1271.
44. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347 ( 25 ): 1999-2009.
45. Jansen MP, Foekens JA, van Staveren IL, et al. Molecular classifi cation of tamoxifen-resistant breast carcinomas by gene expression profi ling. J Clin Oncol. 2005; 23 ( 4 ): 732-740.
46. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007; 356 ( 3 ): 217-226.
47. Smid M, Wang Y, Klijn JG, et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol. 2006; 24 ( 15 ): 2261-2267.
48. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A. 2005; 102 ( 10 ): 3738-3743.
49. Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med. 2008; 358 ( 26 ): 2796-2803.
50. Massague J. Sorting out breast-cancer gene signatures. N Engl J Med. 2007; 356 ( 3 ): 294-297.
51. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996; 88 ( 20 ): 1456-1466.
52. Hayes DF. Markers of increased risk for failure of adjuvant therapies. Breast. 2003; 12 ( 6 ): 543-549.
53. Tari AM, Lim SJ, Hung MC, Esteva FJ, Lopez-Berestein G. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene. 2002; 21 ( 34 ): 5224-5232.
54. Papadaki I, Mylona E, Giannopoulou I, Markaki S, Keramopoulos A, Nakopoulou L. PPARgamma expression in breast cancer: clinical value and correlation with ERbeta. Histopathology. 2005; 46 ( 1 ): 37-42.
55. Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene. 2003; 22 ( 47 ): 7305-7315.